Alfred C. Feller - Concepedia

Author

Alfred C. Feller

Also Known As

A C Feller, A FELLER, A Feller, A. C. FELLER, A. C. Feller, A. Feller, A.C. FELLER, A.C. Feller, ALFRED C. FELLER, Alfred C Feller

252

Publications

14.7K

Citations

H-Index

Concepts

All Affiliations

University of Lübeck University Hospital Schleswig-Holstein Christian-Albrechts-Universität zu Kiel University of Würzburg Goethe University Frankfurt

About

Alfred C. Feller is an author at University of Lübeck specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	60	6.7K
2	Engineering	4	4	732
3	Health Sciences	3	3	96
4	Natural Sciences	2	2	102
5	Public Health	1	1	17

Alfred C. Feller

124

Publications

12.8K

Citations

H-Index

Page 1

	Year	Citations
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene Benjamin Sadlack, Hartmut Merz, Hubert Schorle, Cell InflammationChronic Inflammatory DiseasesUlcerative Colitis-like DiseaseCytokineAutoimmune Disease	1993	1.7K
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaElderly PatientsMedicineBi-weekly Chop-14	2008	1.1K
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling Michael Hummel, Stefan Bentink, Hilmar Berger, New England Journal of Medicine	2006	1K
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer Merle Hanke, Kai P. Hoefig, Hartmut Merz, Urologic Oncology Seminars and Original Investigations Tumor BiologyUrinary Bladder CancerUrologyEngineeringUrological Research	2009	636
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry Alessandro Pastore, Vindi Jurinović, Robert Kridel, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyFollicular Lymphoma	2015	608
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma Heike Horn, Marita Ziepert, Claudia Becher, Blood	2013	540
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Nathalie Mourad, Nicolas Mounier, Josette Brière, Blood	2008	334
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the <i>European MCL Network</i> Markus Tiemann, Carsten Schrader, Wolfram Klapper, British Journal of Haematology	2005	316
Clinical Impact of the Cell-of-Origin Classification and the <i>MYC</i> / <i>BCL2</i> Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group Annette M. Staiger, Marita Ziepert, Heike Horn, Journal of Clinical Oncology	2017	214
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL German Ott, Marita Ziepert, Wolfram Klapper, Blood	2010	200

Page 1